8-K: J&J Reports Q1 2026 Results, Raises Full-Year Outlook

Johnson & Johnson announced strong first-quarter 2026 results, with sales up 9.9% and earnings per share of $2.14, leading the company to raise its full-year 2026 guidance.

Summary

• Johnson & Johnson reported first-quarter 2026 sales of $24.1 billion, a 9.9% increase year-over-year, with operational growth of 6.4%.
• Diluted earnings per share (EPS) for the quarter were $2.14, while adjusted EPS was $2.70.
• The company raised its full-year 2026 outlook, now expecting reported sales of $100.8 billion (7.0% growth at the midpoint) and adjusted EPS of $11.55 (7.1% growth at the midpoint).
• Key product drivers included growth in Oncology (DARZALEX, CARVYKTI, ERLEADA, RYBREVANT/LAZCLUZE), Immunology (TREMFYA), and Neuroscience (SPRAVATO).
• MedTech segment growth was driven by electrophysiology products, Abiomed, and Shockwave in Cardiovascular, and trauma in Orthopaedics.
• The Board of Directors declared a 3.1% increase in the quarterly dividend to $1.34 per share, marking the 64th consecutive year of dividend increases.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to raised guidance and strong dividend history, though the GAAP net earnings decline warrants attention.

Positives

• Reported sales growth of 9.9% to $24.1 billion in Q1 2026.
• Raised full-year 2026 guidance for reported sales to $100.8 billion (7.0% growth at midpoint).
• Increased full-year 2026 adjusted EPS guidance to $11.55 (7.1% growth at midpoint).
• Achieved 64 consecutive years of quarterly dividend increases, with a 3.1% hike to $1.34 per share.
• Innovative Medicine segment operational sales grew 7.4%, driven by key products in Oncology, Immunology, and Neuroscience.
• MedTech segment operational sales grew 4.6%, supported by Cardiovascular and Orthopaedics.

Negatives

• Reported Net Earnings decreased by 52.4% to $5.235 billion, and diluted EPS decreased by 52.9% to $2.14.
• Adjusted Net Earnings decreased by 1.4% to $6.614 billion.
• Adjusted EPS (diluted) decreased by 2.5% to $2.70.
• STELARA in Immunology and IMBRUVICA in Oncology had a negative impact on growth.
• Free Cash Flow decreased significantly to approximately $1.5 billion from $3.379 billion in the prior year.

Risks

• Economic factors, such as interest rate and currency exchange rate fluctuations.
• Competition, including technological advances, new products, and patents attained by competitors.
• Challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals.
• Uncertainty of commercial success for new and existing products.
• Challenges to patents and the impact of patent expirations.
• Ability to successfully execute strategic plans, including restructuring plans.
• Impact of business combinations and divestitures.
• Manufacturing difficulties or delays, internally or within the supply chain.

Future Outlook

Johnson & Johnson raised its full-year 2026 guidance, now projecting reported sales between $100.3 billion and $101.3 billion (midpoint $100.8 billion, 7.0% growth) and adjusted diluted EPS between $11.45 and $11.65 (midpoint $11.55, 7.1% growth). The company anticipates solidifying a path to double-digit growth by the end of the decade.

Management Comments

• "Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact," said Joaquin Duato, Chairman and Chief Executive Officer.
• "The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe."
• "These advancements have the potential to transform patient outcomes and create sustainable, long-term value for shareholders."

Industry Context

StockSavvy.ai notes that Johnson & Johnson's Q1 2026 performance and raised outlook align with broader trends in the pharmaceutical and MedTech sectors, emphasizing innovation and strategic portfolio management. The company's focus on key therapeutic areas and new product approvals reflects a competitive landscape where sustained R&D investment and market access are critical for growth.

Comparison to Industry Standards

• Johnson & Johnson's reported sales growth of 9.9% in Q1 2026 exceeds the typical quarterly growth rates seen in large-cap diversified healthcare companies, which often range from 3-7%.
• The company's adjusted operational sales growth of 5.3% demonstrates resilience in its core business operations, excluding currency and M&A impacts, which is a key metric for evaluating underlying performance against industry peers.
• The 64-year streak of consecutive dividend increases is a significant outlier, far surpassing the average dividend growth history of most S&P 500 companies, indicating exceptional financial stability and shareholder return commitment.
• The company's raised full-year guidance suggests confidence in its ability to navigate market dynamics and achieve growth targets, potentially outperforming competitors who may be facing more conservative outlooks due to economic uncertainties or specific product cycle challenges.

Legal Proceedings

• The reconciliation of non-GAAP measures mentions 'Litigation related' adjustments, indicating ongoing legal matters that impact GAAP financial results.

Stakeholder Impact

• Shareholders: Benefit from a 3.1% increase in quarterly dividend and potential for long-term value creation through raised guidance and innovation pipeline.
• Employees: May see continued focus on innovation and growth, potentially impacting performance incentives.
• Customers (Healthcare Providers/Patients): Access to new and improved treatments and medical devices, such as ICOTYDE, TECVAYLI, and VARIPULSE Pro.
• Suppliers: Continued demand for products and services supporting J&J's manufacturing and R&D operations.

Next Steps

• Continue to monitor the performance of key growth drivers in Innovative Medicine and MedTech.
• Evaluate the impact of product approvals such as ICOTYDE and TECVAYLI plus DARZALEX FASPRO.
• Observe the progress of the Enterprise Business Review scheduled for December 8, 2026.
• Track the integration and performance of recent acquisitions and the impact of divestitures.

Key Dates

Recommendation

The company demonstrated solid operational performance and raised its full-year guidance, alongside a consistent dividend increase, which are positive indicators. However, the significant drop in reported net earnings and EPS, even if explained by non-recurring items, alongside the decrease in adjusted net earnings and EPS, suggests a cautious approach is warranted. The company's long-term prospects remain strong, but near-term headwinds and the need to fully digest the impact of the litigation adjustments and ongoing restructuring warrant a 'hold' rating until further clarity emerges.

Keywords

Johnson & Johnson, JNJ, Q1 2026 Results, Earnings, Sales, Dividend, Healthcare, Pharmaceuticals